Diabetes Management Update: A Patient-Centered Approach- Pharmacist

  Price  $6.95

  Credits  1.5

Clear


Format
According to the Centers for Disease Control (CDC), an estimated 30 million people in the US have diabetes (9% of the US population). Only 23 million have an official diagnosis, while 7 million are undiagnosed. The prevalence of diabetes is highest in American Indians/Alaskan Natives at 15%, followed by African Americans (13%), people of Hispanic ethnicity (12%) and Caucasians (7%). An estimated 84 million people in the US have prediabetes (34% of the population) – including nearly half of adults aged 65 years old and older. The prevelance of diabetes is increasing – by the year 2050, as much as 33% of the population will have the disease. This has significant implications on the long term micro- and macrovascular complications, coexisting health conditions, and costs associated with diabetes. In fact, the total healthcare costs of diagnosed diabetes increased 26% from 2012 to 2017, to $327 billion. People with diabetes incur medical expenses that are 2.3 times higher than those of individuals without diabetes. Because the population most affected by the increase in diabetes prevalence and costs are adults aged 65 years, it has a major impact on our Medicare program.
$6.95

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharmacist

Author
Katherine S. O'Neal
PharmD, MBA, BCACP, CDCES, AE-C, CLS, FADCES
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • Discuss the intention of patient-centered, comprehensive care for individuals with diabetes. Summarize the new recommendations for patients with diabetes who also have dyslipidemia and/or hypertension.
  • Describe specific cardiovascular and/or chronic kidney disease benefits of glucagon-like peptide-1 (GLP-1) agonists and sodium glucose cotransporter-2 (SGLT-2) inhibitors, as outlined in the ADA Standards of Care.
  • Discuss the insulin therapy updates in the ADA Standards of Care, including new considerations for older adults.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    20-878274
  • Universal Activity Number:
    Pharmacist : 0798-0000-21-198-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.